A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer’s Disease
TITLE:
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
MEDICAL CONTION:
Alzheimer's Disease
AGE:
65 Years to 80 Years
SEX/GENDER:
Male & Female